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In this issue of Osteoporosis International we present several
papers representing common approaches to the evaluation of
fracture risk [1–5]. This represents a considerable change for
the field, moving from descriptions of risk as “relative risk,”
as occurs on the output of DXA equipment, to what might be
called “absolute risk” or “real risk,” neither of which is an
adequate description. The model allows an assessment of the
likelihood of hip or major osteoporosis-related fracture within
a specific time frame (10 years) for individual patients.
These analyses result from a “mega-analysis” conducted
by a team of investigators on behalf of the World Health
Organization, led by Dr John Kanis. In this study Kanis and
colleagues took data from epidemiological studies from the
USA, Europe, Australia and Asia and determined the
factors that were common to all that independently
increased the risk of fractures in the aging population.
They then modeled overall fracture risk using these factors,
making the model generally usable throughout the world. In
order to apply the model, each country simply would have
to know the epidemiology of osteoporosis-related fractures,
their outcomes, and mortality rates, and risk models could
be calculated. Where country-specific fracture data are not
available, data from other countries with similar ethnic
make-up can be substituted, with the realization that risk
calculations made in this way are more prone to error.
Using these risk assessments a health economic strategy
can be formulated for each country, based on acceptable
levels of resource utilization, to determine at what level of
risk it would be cost effective to intervene. To do this
requires more information than fracture epidemiology,
including costs and the efficacy of the intervention
strategies to reduce the risk of the fractures considered in
the model, something that has to be derived from clinical
trial data, which may or may not address these specific
fractures. From these data intervention strategies can be
developed, which will vary from country to country.
This methodology brings this field somewhat into line
with cardiovascular disease and breast cancer risk reduc-
tion, where data from Framingham have been used in this
fashion in clinical decision making, as has the Gail model
for the latter. Clearly, however, this does not change the
concept of osteoporosis defined as a bone mineral density
(at the hip) 2.5 SD below the average value for young
adults. In at least some countries this will, by itself, convey
a risk of sufficient magnitude to require intervention. The
model does allow the identification of those in the low
BMD range (T-score –1 to –2.5) who have the highest risk
of fracture and would benefit for treatment. This is an
important advance, since overall in this population the risk
of fracture is low, but by virtue of numbers, total fractures
exceed those occurring in persons with osteoporosis. Two
other features of the model are clinically important. It
allows for risk stratification in men, and across race.
Finally, it aids in identifying persons with co-morbid
conditions that increase fracture risk, and allows targeting
of the high-risk populations here for intervention.










The concept and the model development have been
supported by the IOF and NOF, and both organizations
strongly advocate its use in clinical decision making. The
National Osteoporosis Foundation in the USA will be
releasing a new Physician’s Guide applying the WHO
algorithm to postmenopausal women and older men in the
US population (www.nof.org) that is based upon the data in
the papers in this issue from the NOF Guide Committee.
Other support from the UK and Japan is indicated by
inclusion of papers reflecting the adaptation of the model to
those populations. Data for other countries such as Sweden
have already been published, and we hope that others will
follow.
Finally, this issue contains European guidelines on the
diagnosis and management of osteoporosis from the scientific
committee of the European Society for the Clinical and
Economic Evaluation of Osteoporosis (ESCEO) that review
themost recent evidence on clinical efficacy/safety of treatments
and integrate the recent developments described above [6].
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